EUVIMEDEUVIMED entdecken
Crossref

A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer

Ein neuartiger Risikovorhersagescore für klinisch signifikante Blutungen bei mit Antikoagulanzien behandelten Patient:innen mit venöser Thromboembolie und aktiver Krebserkrankung

Alexander T Cohen iD, Christopher Wallenhorst iD, Satarupa Choudhuri, Ayman Nassar, Kevin G Pollock iD, Carlos Martinez iD

Thrombosis and Haemostasis · 01.04.2024 · 124 (04) · 324-336

DOI: 10.1055/a-2145-7238 ↗

Auf einen Blick

Bei 15.749 Patient:innen mit Ca-VTE sagte ein neuer Score signifikante Blutungen innerhalb von 180 Tagen mit mäßiger Genauigkeit voraus. Die C-Statistik betrug 0,70.

Fragestellung

Kann ein neuer Risikoscore bei Patient:innen mit Ca-VTE unter Antikoagulation das Blutungsrisiko vorhersagen?

Methode

Kohortenstudie mit Daten aus dem UK Clinical Practice Research Datalink (2008–2020); Beobachtung bis 180 Tage; Score aus sub-distribution hazard ratios, Leistung per Cross-validation.

Ergebnisse

15.749 Patient:innen; 537 signifikante Blutungen, 161 Major-Blutungen, 376 CRNMB-H. C-Statistik: 0,70 (95 %-KI 0,65–0,75) für signifikante Blutungen; 0,76 (0,68–0,84) für Major-Blutungen; 0,67 (0,61–0,73) für CRNMB-H.

Schlussfolgerung der Autor:innen

Der Risikoscore könnte Patient:innen mit Blutungsrisiko identifizieren und bei der Festlegung der Behandlungsdauer helfen.

Kernaussagen

  • Score für signifikante Blutungen bei Ca-VTE entwickelt
  • C-Statistik 0,70 (95 %-KI 0,65–0,75)
  • Risikofaktoren u. a. bestimmte Tumorarten, Metastasen und frühere Blutung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.04.2024. Verfasst von Alexander T Cohen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Guy's and St Thomas' Hospitals, NHS Foundation Trust, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Pfizer Ltd. and Bristol-Myers Squibb.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer-associated venous thromboembolism (Ca-VTE) treatment with anticoagulation is associated with bleeding complications and there are limited data on risk factors. Current models do not provide accurate bleeding risk prediction.

Methods

UK Clinical Practice Research Datalink data (2008–2020) were used to generate a cohort of patients with anticoagulant initiation for first Ca-VTE. Patients were observed up to 180 days for significant bleeding including major bleeding and clinically relevant nonmajor bleeding requiring hospitalization (CRNMB-H). A scoring scheme was developed from sub-distribution hazard ratios, and its discrimination (expressed by the C-statistic) estimated from cross-validation.

Results

A total of 15,749 patients with Ca-VTE and anticoagulant treatment were included. In total, 537 significant bleeding events, 161 major bleeds, and 376 CRNMB-H were identified after adjudicated review in 4,914 person-years of observation. Incidence rates of 3.3 and 7.7 per 100 person-years were noted for major bleeding and CRNMB-H. Independent predictors of significant bleeding included cancer of the bladder, central nervous system, cervix, kidney, melanoma, prostate and upper gastrointestinal tract, metastases, minor surgery, minor trauma, and history of major bleeding or CRNMB (before or after the Ca-VTE diagnosis). Patients recognized as low, medium, and high risk (30.4, 56.8, and 1.7% of the population, respectively) had a 6-month significant bleeding incidence rate of 5.1, 19.0, and 56.5 per 100 person-years, respectively. Overall C-statistic for significant bleeding was 0.70 (95% confidence interval: 0.65–0.75), and 0.76 (0.68–0.84) and 0.67 (0.61–0.73) for major bleeding and for CRNMB-H, respectively.

Conclusion

This risk score may identify patients at risk of significant bleeding, while also helping to determine treatment duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismNeoplasmsMaleFemaleHumansHemorrhageAnticoagulantsRisk Factors

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Haematology, Guy's and St Thomas' Hospitals, NHS Foundation Trust, King's College London, London, United Kingdom.
  • Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany.
  • Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.
  • Bristol Myers Squibb Pharmaceuticals Ltd., Uxbridge, Middlesex, United Kingdom.

ORCID-Profile: Alexander T Cohen, Christopher Wallenhorst, Kevin G Pollock, Carlos Martinez

Förderung

  • Pfizer Ltd. and Bristol-Myers Squibb

Zitieren

APA

Cohen, A. T., Wallenhorst, C., Choudhuri, S., Nassar, A., Pollock, K. G., & Martinez, C. (2024). A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer. Thrombosis and Haemostasis, 124(04), 324-336. https://doi.org/10.1055/a-2145-7238

Vancouver

Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer. Thrombosis and Haemostasis. 2024;124(04):324-336. doi:10.1055/a-2145-7238

BibTeX
@article{Cohen2024,
  author = {Cohen, Alexander T and Wallenhorst, Christopher and Choudhuri, Satarupa and Nassar, Ayman and Pollock, Kevin G and Martinez, Carlos},
  title = {A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {04},
  pages = {324--336},
  doi = {10.1055/a-2145-7238}
}
Kostenlos starten →